In the era of cell and gene therapy, how robust is RWE collection?

 

  • “Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching”
  • “Existing data collection infrastructure in indications with potential cell or gene therapies launches in the next five years in the UK is overall not sufficient to facilitate outcomes-based reimbursement.”

Click here to see the source article 

Reference

Jørgensen, J., Mungapen, L., & Kefalas, P. (2019). Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching. Journal of market access & health policy7(1), 1573164. doi:10.1080/20016689.2019.1573164

 

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

 

Posted in Blogs.